INTERGRATED DIA.H DL 025 (8I8) - Net Assets
Based on the latest financial reports, INTERGRATED DIA.H DL 025 (8I8) has net assets worth €3.55 Billion EUR (≈ $4.15 Billion USD) as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.77 Billion ≈ $7.91 Billion USD) and total liabilities (€3.22 Billion ≈ $3.76 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore INTERGRATED DIA.H DL 025 cash conversion from operations to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.55 Billion |
| % of Total Assets | 52.47% |
| Annual Growth Rate | 10.26% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 14.57 |
INTERGRATED DIA.H DL 025 - Net Assets Trend (2021–2025)
This chart illustrates how INTERGRATED DIA.H DL 025's net assets have evolved over time, based on quarterly financial data. Also explore 8I8 total asset value for the complete picture of this company's asset base.
Annual Net Assets for INTERGRATED DIA.H DL 025 (2021–2025)
The table below shows the annual net assets of INTERGRATED DIA.H DL 025 from 2021 to 2025. For live valuation and market cap data, see market value of INTERGRATED DIA.H DL 025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.13 Billion ≈ $4.83 Billion |
+18.03% |
| 2024-12-31 | €3.50 Billion ≈ $4.09 Billion |
+12.86% |
| 2023-12-31 | €3.10 Billion ≈ $3.63 Billion |
+26.72% |
| 2022-12-31 | €2.45 Billion ≈ $2.86 Billion |
-12.43% |
| 2021-12-31 | €2.79 Billion ≈ $3.27 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to INTERGRATED DIA.H DL 025's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 67.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.60 Billion | 76.75% |
| Other Components | €786.51 Million | 23.25% |
| Total Equity | €3.38 Billion | 100.00% |
INTERGRATED DIA.H DL 025 Competitors by Market Cap
The table below lists competitors of INTERGRATED DIA.H DL 025 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sovereign Metals Ltd
AU:SVM
|
$288.38 Million |
|
Orbit Technologies Ltd
TA:ORBI
|
$288.39 Million |
|
Fresnillo PLC
LSE:FRES
|
$288.52 Million |
|
Formosan Union Chemical Corp
TW:1709
|
$288.55 Million |
|
Tcc Steel
KO:002710
|
$288.32 Million |
|
Israel Land Development Urban Renewal Ltd
TA:ILDR
|
$288.24 Million |
|
Borosil Limited
NSE:BOROLTD
|
$288.17 Million |
|
Nuveen Core Plus Impact Fund
NYSE:NPCT
|
$288.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INTERGRATED DIA.H DL 025's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,710,149,000 to 3,383,114,000, a change of 672,965,000 (24.8%).
- Net income of 1,262,207,000 contributed positively to equity growth.
- Dividend payments of 535,143,000 reduced retained earnings.
- Other factors decreased equity by 54,099,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.26 Billion | +37.31% |
| Dividends Paid | €535.14 Million | -15.82% |
| Other Changes | €-54.10 Million | -1.6% |
| Total Change | €- | 24.83% |
Book Value vs Market Value Analysis
This analysis compares INTERGRATED DIA.H DL 025's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.30 | €0.47 | x |
| 2022-12-31 | €3.59 | €0.47 | x |
| 2023-12-31 | €4.46 | €0.47 | x |
| 2024-12-31 | €4.66 | €0.47 | x |
| 2025-12-31 | €5.82 | €0.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INTERGRATED DIA.H DL 025 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 37.31%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.07%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 2.54x
- Recent ROE (37.31%) is above the historical average (35.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 54.69% | 27.04% | 0.84x | 2.41x | €1.15 Billion |
| 2022 | 25.12% | 15.01% | 0.68x | 2.46x | €325.70 Million |
| 2023 | 19.05% | 12.38% | 0.71x | 2.15x | €242.41 Million |
| 2024 | 39.76% | 18.84% | 0.80x | 2.63x | €806.42 Million |
| 2025 | 37.31% | 16.07% | 0.91x | 2.54x | €923.90 Million |
Industry Comparison
This section compares INTERGRATED DIA.H DL 025's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $4,136,082,443
- Average return on equity (ROE) among peers: -22.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INTERGRATED DIA.H DL 025 (8I8) | €3.55 Billion | 54.69% | 0.91x | $288.34 Million |
| IZOTROPIC CORP. (1R3) | $-4.86 Million | 0.00% | 0.00x | $10.32 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $19.89 Million | -11.18% | 0.45x | $1.06 Million |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $24.45 Billion | 8.28% | 0.21x | $500.93 Million |
| Check-Cap Ltd (7CC) | $23.69 Million | -74.17% | 0.06x | $8.64 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $32.00 Million | -74.44% | 0.67x | $2.85 Million |
| GENINCODE PLC LS -01 (9PL) | $13.72 Million | -30.19% | 0.11x | $6.89 Million |
| INOVIQ LTD. (EGQ0) | $43.22 Million | -28.62% | 0.12x | $25.34 Million |
| Eurofins Scientific SE (ESF0) | $4.58 Billion | 10.37% | 1.40x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $8.07 Billion | 1.90% | 1.16x | $7.52 Billion |
About INTERGRATED DIA.H DL 025
Integrated Diagnostics Holdings plc operates as a consumer healthcare company that provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron… Read more